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248 I.C. Withrock et al.We also discuss two genetic conditions that lead to infectious disease hypersusceptibility,
although we did not cover the large number of immunologic defects leading to infectious dis-
ease hypersusceptibilities. Four of the resistance-associated pairings (malaria/hemogloginopa-
thies, cholera/cystic fibrosis, tuberculosis/Tay-Sachs, and mycotic abortions/phenylketonuria)
appear to be a result of selection pressures in geographic regions in which the specific infec-
tious agent is endemic. The other pairings do not appear to be based on selection pressure and
instead may be serendipitous. Nonetheless, research investigating these relationships may
lead to treatment options for the aforementioned diseases by exploiting established mecha-
nisms between genetically affected cells and infectious organisms. This may prove invaluable
as a starting point for research in the case of diseases that currently have no reliably curative
treatments, e.g., HIV, rabies, and Ebola.
Copyright ª 2015, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Some genetic conditions can confer resistance to specific
infectious diseases. It is theorized that these genotypes are
preferentially maintained in populations regularly exposed
to certain infectious agents, especially those with high
virulence. The protection afforded by these conditions has
provided the impetus for understanding these genetic
mechanisms of resistance that can potentially be exploited
for developing novel therapies or improving current thera-
pies. This review describes a number of these resistances,
the molecular bases for each resistance, and therapeutic
implications from the resistance. We also discuss two re-
lationships that lead to infectious disease hyper-
susceptiblity, which also provides valuable information that
has been used or will be used to develop therapies.
This review is organized based on a description of four
genetic conditions/infectious resistance pairings in which
there appears to be a selection pressure. The first of which is
sickle cell anemia (and other hemoglobinopathies) and
malaria in geographic regions in which the malaria-causing
parasite and vector is endemic.1 Interestingly, this disease
complex leads to increased susceptibility to respiratory in-
fections through a mechanism independent of hemoglobin.
The second pair involving a putative selection pressure is
cystic fibrosis, which involves a mutation encoding a
defective chloride channel. In unaffected individuals, this
channel can be exploited by diarrhea-producing enter-
opathogens. The derangement of this channel may result in
resistance to the enteric effects of cholera, and the cystic
fibrosis genotype has a higher prevalence in regions in
which cholera is or was endemic.2
The third selection pressure-associated pair involves Tay-
Sachs disease, a lysosomal storage disease characterized by
deficiency of hexosaminidase A. Historically, Ashkenazi
Jews had a high prevalence of the Tay-Sachs allele and a low
prevalence of tuberculosis caused by Mycobacterium
tuberculosis, a relationship that may be related to crowded
environments associated with this ethnic population and
concentration of Mycobacterium tuberculosis.3
Yet another relationship with a putative selection pres-
sure is phenylketonuria, a metabolic genetic disorder in
which phenylalanine accumulates to toxic levels in theaffected individual. Women who are heterozygotes for the
disorder are significantly less sensitive to the abortifacient
activities of the mycotoxin designated as ochratoxin A. This
relationship appears to be relevant in moist regions in
which pathogenic fungi are endemic.4
Three other relationships do not appear to have a se-
lection pressure, one of which is congenital disorder of
glycosylation 2b (CDG-IIb) which leads to impaired glyco-
sylation of proteins and thus confers resistance to viruses
that have glycosylated capsids.5 The second “spurious”
relationship involves myasthenia gravis in which auto-
antibodies attack the acetylcholine receptor that is coin-
cidentally exploited as a docking site for the rabies virus;
this competition may lead to resistance to rabies.6 Finally,
NiemannePick C1 disease is a lysosomal storage disorder in
which a faulty cholesterol transporter leads to abnormal
accumulation of cholesterol within lysosomes. The Ebola
virus apparently uses this transporter and thus its
dysfunction impairs viral pathogenicity in patients with
NiemannePick C1 disease.7
It is of note that a particular genetic disorder leads to
infectious disease hypersusceptibility, and this relationship
has provided the basis for a preventative. Specifically, the
relationship between hemosiderosis and typhoid fever has
led to the development of a vaccine that intervenes in this
relationship.
This literature review discusses the potential benefits
garnered from further study of the pathways associated
with these genetic conditions and infectious disease resis-
tance (or hypersusceptibility). A summary of the current
state of research is presented in Table 1. The more we
understand about the link between these genetic condi-
tions and the infectious disease resistances, the easier it
will be to exploit the mechanism for therapeutic uses.
When trying to develop therapies, the most difficult part is
often finding a starting point for research. The nature of
the human condition provides us with these starting points.
Resistance to malaria and the sickle trait
Resistance to malaria has been linked to a number of con-
ditions including hemoglobinopathies, enzymopathies, and
the absence of an erythrocyte surface protein. Other
Table 1 Summary of the genetic disorder and infectious disease pairings described herein.
Genetic disorder and
infectious disease
Genetic basis for the disorder Clinical manifestations of the
disorder
Potential therapies for the disorder or
the infection based on the
relationship
Resistance or
hypersusceptibility
Sickle cell trait and
malaria
Mutations encoding hemoglobin or
enzymes vital to erythrocyte
metabolism
Anemia Hydroxyurea to increase the
expression of a hemoglobin subtype
that is unaffected by malaria8
Resistance
Sickle cell trait and
pneumococcal
pneumonia
ibid ibid ibid Hypersusceptibility
Cystic fibrosis and
cholera
Mutations in a gene encoding a
chloride channel (CFTR)
Excessive respiratory secretions that
provide a hospitable environment for
bacterial growth
Inhibiting the CFTR may prevent the
gastrointestinal fluid loss associated
with cholera2
Resistance
Tay-Sachs disease and
tuberculosis
Mutations in the gene encoding a-
hexosaminidase
Mental and physical disabilities
leading to death in infants
Up-regulation or activation of
-hexosaminidase may have
mycobactericidal effects18
Resistance
Phenylketonuria and
mycotic abortions
Mutations in the gene encoding
phenylalanine hydroxylase
Mental retardation, seizures, etc. Inhibiting phenylalanine hydroxylase,
minimizing phenylalanine intake, or
glycomacropeptides, (nutritives that
curb aromatic amino acids in the
plasma of the host33) may prevent the
abortions although these strategies
may be deleterious to the fetus
Resistance
Congenital disorder of
glycosylation IIb and
viral infections
Mutations in the gene encoding
mannosyl-oligosaccaride glucosidase
Developmental disorders, hypotonia,
hypoglycemia, protein-losing
enteropathy
Treating or preventing viral infections
with MOGS inhibitors
(castanospermine, N-
butyldeoxynojirimycin, and
deoxynojirimycin1922) or other
glycosylation inhibitors (2-
deoxyglucose and tunicamycin23)
Resistance
Myasthenia gravis and
rabies
Auto-antibodies directed at
cholinergic receptors
Paralysis and respiratory failure Cholinergic antagonists may block
rabies virus translocation
Resistance
NiemannePick C1
disease and filovirus
infection
Mutations that lead to NPC1
deficiencies in lysosomes
Hepatospleno-megaly,
thrombocytopenia, and neurologic
deficits
NPC1 inhibition for preventing
filovirus infection
Resistance
Hemosiderosis and
typhoid fever
Mutations in genes encoding for
proteins that regulate erythrocytic
iron
Polycythemia and hemorrhage Blockade of the siderophore receptor
protein to prevent salmonelloses32
Hypersusceptibility
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250 I.C. Withrock et al.genetic conditions can lead to resistance to malaria, but
these three specific conditions provide specific insights into
anti-malarial strategies.
Hemoglobinopathies
Thalassemias and other hemoglobinopathies, including
sickle cell disease, are among the most common single-
gene disorders in humans. Thalassemia disorders arise from
alterations in either the a or b globin chain of hemoglobin.
In the case of sickle cell disease, hemoglobin S is dysfunc-
tional while fetal hemoglobin (hemoglobin F) is spared.
Malaria susceptibility and hemoglobin S are directly linked;
the dysfunctional hemoglobin S ultimately prevents further
erythrocyte invasion and intra-erythrocyte growth of Plas-
modium. That is, infection still occurs but the disease does
not progress. Based on these findings, hydroxyurea has
been explored as a chemotherapeutic agent that induces
the production of wild-type fetal hemoglobin (hemoglobin
F), which serves as a fully functional oxygen-carrying pro-
tein. The hydroxyurea-mediated increased expression of
hemoglobin F leads to decreased expression of hemoglobin
S, ultimately minimizing malarial susceptibility.8
Enzymopathies
Glucose-6-phosphate dehydrogenase (G6PD) deficiency re-
sults in erythrocytes that are more prone to suffering
damage. The invasion of malarial parasites exacerbates this
condition, making the cells highly susceptible to phagocy-
tosis. Infected G6PD-deficient erythrocytes are morpho-
logically different compared to non-infected ones and are
thus hypersusceptible to phagocytosis. Another enzymop-
athy involves pyruvate kinase deficiency leading to altered
membrane rigidity of erythrocytes, thus preventing Plas-
modium invasion. Moreover, pyruvate kinase deficiency
significantly reduces the intracellular concentration of
glucose, a vital source of energy for the intra-cellular life
cycle of Plasmodium. As such, both G6PD and pyruvate ki-
nase have been recognized as important drug targets
against P. falciparum.9
Erythrocyte polymorphisms
In contrast to thalassemais and enzymopathies, the Duffy
antigen represents an extracellular-based resistance
mechanism. The Duffy antigen, a receptor for chemokines,
is present on the surface of erythrocytes. This antigen is
also an obligatory binding site for the malarial toxin
secreted by P. vivax. A point mutation in the Duffy gene
leads to lack of expression of the encoded receptor and
thus negates P. vivax toxin attachment. This innocuous
polymorphism is the most common in Papua New Guinea
and Western Africa, which may explain why infection of P.
vivax is uncommon in these areas of the world.10
Sickle cell anemia and pneumococcal infections
While sickle anemia confers resistance to malaria, the
condition renders the patient hypersusceptible to pneu-
mococcal infections. Because of the hypoxia associatedwith the anemia, the respiratory endothelium is hyperac-
tive and overexpresses the receptor for platelet-activating
factor.11 This receptor is a docking site for Streptococcus
pneumoniae,12 and thus the receptor hyperexpression
provides ample attachment sites for the infection by this
bacterial pathogen.
In summary, the molecular bases of malarial resistance
vary but a common theme involves the structure of the
erythrocyte. These mechanisms of resistance have provided
insight into pharmacologic targeting of the malarial infec-
tion. It is fortuitous that the innocuous absence of the Duffy
antigen leads to resistance to a certain type of malaria.
Targeting the Duffy antigen is therefore a meritorious
strategy for treatment, and it will be advantageous to find
an orthologous protein for P. falciparum infection. Indeed,
this type of resistance mechanism is the most useful since
the lack of this particular protein has no apparent conse-
quence to the individual, and thus targeting the protein
should have little adverse effect.Cystic fibrosis and resistance to cholera
Cystic fibrosis (CF) is caused by an autosomal recessive
mutation in a gene that codes for a chloride channel
designated as the cystic fibrosis transmembrane conduc-
tance regulator (CFTR).13,14 Homozygous recessive in-
dividuals express a defective chloride channel, and as a
result are unable to osmotically decrease viscosity of mu-
cous secretions. This increased viscosity leads to decreased
ciliary mucus clearance in the lungs and a rise in suscepti-
bility to pulmonary infections, ultimately leading to respi-
ratory failure. Enterocyte secretions are similarly effected
as a result of the defective chloride transport in the gut.
Current treatment of CF involves intensive regimens that
improve the hydration of secretions (promoting ciliary
clearance), as well as nutritional support, prevention of
pulmonary infections, and management of chronic airway
inflammation.14
CF has a high fatality rate13 yet there is an increased
prevalence in those of Caucasian/European ancestry, rela-
tive to those of African descent.14 The prevalence of het-
erozygous CF carriers is even higher and the current
differences in allele frequencies have been attributed to
cholera outbreaks in the 19th century. This is due to the
supporting evidence that suggests CF heterozygousity
conferred a survival advantage during the outbreak
periods.14
One proposed mechanism for an evolutionary advantage
afforded by CFTR mutations relates to the virulence of
cholera in affected individuals. The etiologic agent, Vibrio
cholerae, produces a toxin that constitutively activates
guanine nucleotide-binding proteins that in turn hyper-
activate the same chloride channels affected by mutations
in the CFTR gene.13 This hyperactivation causes a profound
secretory diarrhea (see Fig. 1). In murine model studies,
heterozygous mice were less susceptible to the cholera toxin
and consequently did not suffer from symptoms as severe as
seen in mice with normal CFTR function. It is postulated that
this result was due to heterozygous mice having only 50% of
the functioning chloride channels comparedwith awild-type
mouse. The decrease in functioning chloride channels
Figure 1 Top, cartoon of the mechanism of diarrhea mediated by Vibrio cholerae in intestinal cells from an individual with an
intact and fully functional CFTR. The bacteria releases a toxin that constitutively activates an intracellular G protein, which
consequently activates adenylate cyclase. Adenylate cyclase catalyzes an ATP/cAMP reaction and the product of this reaction
eventually activates CFTR. The activated CFTR facilitates a chloride ion movement into the gut lumen, which causes an osmotic
loss of sodium ions and water into the lumen. The net result is a watery diarrhea. Bottom, cartoon of the mechanism of resistance
to Vibrio cholerae in intestinal cells from an individual with one or two alleles for the cystic fibrosis phenotype. As per the top
panel, the bacteria releases a toxin, the G protein is activated, adenylate cyclase is activated and cAMP is produced. Because of
the mutant allele(s) encoding the CFTR, there are either inadequate numbers or a complete absence of fully functional CFTRs to
facilitate the chloride loss into the lumen.
Resistance to infectious diseases 251reduced the mass influx of ions, thus ameliorating diar-
rhea.13 Research concerning the CFTR chloride channel and
its role in intestinal secretions resulted in potentially novel
therapies for cholera. The volume of fluid losses seen in
cholera cases could be reduced by pharmacologic inhibition
of CFTR and chloride secretions.2
Tay-Sachs disease and resistance to
tuberculosis
Tay-Sachs is a rare genetic disease that results in an
abnormal accumulation of neuronal lipids caused by a
defective lysosomal enzyme, a-hexosaminidase. Alleles for
this disease are more prevalent in certain populations, the
most well-known being the Ashkenazi Jews. Although
controversial, it has been hypothesized that perpetuation
of this allele is associated with the selective advantage it
provides protection against Mycobacteria tuberculosis, the
causative agent for the highly infectious disease tubercu-
losis. Rotter et al15 suggest that Ashkenazi Jews were sub-
jected to a stronger selective force than other ethnic
groups due to segregation, crowded town environments,
and a lack of immigration. Observations of descendent
populations revealed a lower frequency of tuberculosis-
related deaths in Ashkenazi Jews when compared to non-
Jewish populations from similar areas.15 Another studyshowed that the frequency of the Tay-Sachs gene in
Ashkenazi Jews correlated with areas of the highest
tuberculosis incidence,16 suggesting a protective effect.
It is now known that carriers of the Tay-Sachs gene have
increased production of the b-subunit of hexosaminidase17
and that the b-subunit is closely associated with increased
host defense against mycobacteria.18 Additionally, cell sur-
face bactericidal activity declined in the absence of b-hex-
osaminidase. It is therefore possible that b-hexosaminidase
is cytotoxic to Mycobacteria tuberculosis, making the or-
ganism more susceptible to macrophage attack.18 In the
advent of drug-resistant tuberculosis, developing drugs that
up-regulate or maintain b-hexosaminidase may prove
beneficial for the treatment of tuberculosis while circum-
venting concerns of antibiotic resistance.
Phenylketonuria and resistance to fungal-
mediated abortions
Phenylketonuria (PKU) is an autosomal recessive metabolic
disorder in which toxic levels of phenylalanine accumulate
due to a non-functional hepatic enzyme, phenylalanine
hydroxylase. Historically, physicians observed that women
who were PKU carriers had a much lower than average
incidence of miscarriages. Woolf et al4 published data
showing that women who were heterozygous for the PKU
252 I.C. Withrock et al.disorder displayed a significantly reduced rate of sponta-
neous abortions, when compared to wild-type homozygous
individuals. This was the most prevalent in Scotland and
Ireland, where the consistent damp climate promotes the
growth of mold and fungi on grains and beans. Aspergillus
spp. produces a mycotoxin known as ochratoxin A which is
teratogenic at low doses and potentially lethal at high
doses. In the case of pregnant women, ochratoxin A can
cross the placenta and cause spontaneous abortions. This
toxin, being an N-acyl derivative of phenylalanine, is a
competitive inhibitor of phenylalanine in the phenylalanyl-
tRNA synthetase-catalyzed reaction thus preventing protein
synthesis, which can be reversed by introducing phenylal-
anine which is in excess in PKU individuals. The high fre-
quency of the PKU gene present in women from this
particular section of Europe, as well as that observed in
Yemenite Jews, may help to protect against sudden mis-
carriages, thus ensuring a normal pregnancy.4Congenital disorder of glycosylation 2b and
resistance to viral infections
Resistance to glycosylation-dependent viral infections
(e.g., HIV-1, dengue, herpes simplex 2, hepatitis C, and
influenza) has been linked to congenital disorder of CDG-
IIb. This condition is caused by defective mannosyl-
oligosaccaride glucosidase (MOGS), which is the initial
enzyme in the processing phase of N-linked oligosaccha-
rides. In this extremely rare condition, the process of
attaching N-glycans to proteins is disrupted, resulting in
dysfunctional glycoprotein synthesis.
Due to the dependence of enveloped viruses on proper
host cell glycosylation for the assembly of their capsid
proteins, it appears that the defective glycosylation in
patients with CDG-IIb hinders cellular entry, cellular egress,
and viral replication for glycosylation-dependent enveloped
viruses. Evidence to support the theory of lowered sus-
ceptibility in those with defective glycosylation has been
documented through a case study of two siblings with CDG-
IIb. These individuals had appropriate immune responses to
non-replicating viruses, but failed to mount a humoral
response to live glycosylation-dependent virus vaccines
MMR and varicella.5 Furthermore, the MOGS inhibitors
castanospermine, N-butyldeoxynojirimycin, and deoxy-
nojirimycin have been shown to lower replication in cells
infected with enveloped viruses such as HIV, dengue, hep-
atitis B and C, and herpes simplex virus-2.19e22 These
findings are additionally supported by the antiviral use of 2-
deoxyglucose and tunicamycin, both of which truncate
glycan polymers and attenuates the replication of certain
viruses.23 In summary, the antiviral effects of defective
glycosylation provide a strong basis for continued research
on the next generation of MOGS inhibitors.Myasthenia gravis and resistance to rabies
Myasthenia gravis (MG) is an autoimmune disorder that in-
volves the destruction of acetylcholine receptors (AChR) by
AChR-specific antibodies. The antibodies produced in MG
patients effectively inhibit neural transmission at theneuromuscular junction by accelerated degradation of re-
ceptors, blocking of acetylcholine-binding sites, and
degradation and simplification of synaptic folds.24 AChRs
are abundant in the post-synaptic nerve endings of the
neuromuscular junction, and the loss of these receptors
leads to pronounced muscle weakness due to inhibited
neural signal transmission.
The rabies virus is a neurotropic rhabdovirus that causes
inflammation in the nervous systems of warm-blooded an-
imals. Although it is known that the rabies virus may enter
the CNS through several routes other than muscle tis-
sue,25,26 research indicates that entry of the virus into the
peripheral nervous system (PNS) may benefit significantly
from replication in skeletal muscles. Furthermore, the
rabies virus preferentially enters through the neuromus-
cular junctions of both the intrafusal and extrafusal mus-
cles.27,28 Infiltration of these muscles is thought to be
augmented by the ability of the rabies virus to bind to
nicotinic AChRs, whereupon the virus enters via receptor-
mediated endocytosis.28 Following initial infection, the
virus enters the PNS where it undergoes replication in the
dorsal-root ganglion and travels to the CNS through retro-
grade transport mechanisms.29 While we are unaware of
documented cases in the literature, to the extent that MG
exerts its effects on musculature by either occupying or
attacking nicotinic AChRs, it is reasonable to suppose that
MG patients will show a diminished likelihood of rabies
infection. Even if MG resulted only in a delay in the spread
of the rabies virus to the PNS, this interval may create the
possibility for immune clearance and additional medical
intervention following initial virus introduction.30 Further
research on the different mechanisms behind AChR degra-
dation in MG patients may offer insight in to new medica-
tions to better prevent rabies virus pathogenicity.NiemannePick C1 disease and resistance to
filoviruses such as Ebola and Marburg
NiemannePick C1 disease is a lysosomal storage disorder in
which cholesterol abnormally accumulates within lyso-
somes. This accumulation occurs due to a shortage of the
NPC1 protein that normally transports cholesterol out of
the lysosome.7 Carette et al7 used an ex vivo assay and
associated NPC1 with the Ebola virus infection process.
Further studies revealed that the Ebola virus poorly infec-
ted NiemannePick C1 disease patient fibroblasts, while
normal infection was observed when expression of wild-
type NPC1 was restored. NPC1-mediated infection was
also observed with another filovirus, the Marburg virus. The
discovery of the NPC1-filovirus relationship has raised the
possibility that Ebola and Marburg virus outbreaks could be
prevented by drugs that block the action of NPC1.Hemosiderosis and hypersusceptibility to
typhoid fever
Hemosiderosis is a genetic condition leading to excess he-
mosiderin and thus excess iron in the blood. Salmonella
enterica is an enteric pathogen that can cause a systemic
infection designated as typhoid fever. Salmonella are
Figure 2 Top, cartoon of the siderophore receptor protein (SRP) and its importance for the survival and growth of Salmonella.
The SRP serves as an iron sieve that is needed for the activation of iron-dependent metabolic and virulence proteins as part of
normal Salmonella physiology. The SRP vaccine yields an anamnestic response resulting in anti-SRP antibodies that block the iron
transport through the SRP. The iron depletion ultimately leads to death of the microbe. Bottom, hemosiderosis and hypersus-
ceptibility to typhoid fever depicted by the activation of Salmonella survival and virulence in the abundance of iron in an individual
with hemosiderosis. The SRP serves as an iron sieve that is needed for the activation of iron-dependent metabolic and virulence
proteins as part of normal Salmonella physiology. The excess of iron in the blood leads to ample activation of Salmonella metabolic
and virulence proteins, culminating in salmonellosis (a.k.a. typhoid fever).
Resistance to infectious diseases 253dependent upon the intake of iron and thus the abundance
of iron can lead to enhanced susceptibility to typhoid fever
in patients afflicted with hemosiderosis.31 This information
has been used to develop an anti-Salmonella vaccine that
blocks iron intake by the bacteria.32 Details of these pro-
cesses are presented in Fig. 2.
Conclusions
The examination of genetic conditions that confer resis-
tance to infectious diseases presented in this article high-
lights mechanisms that could be exploited for potential
therapies. We first discussed genetic conditions that have
persisted to protect populations from considerable calam-
ity due to widespread prevalence of an infectious agent.
Epidemiological data evaluating the spread of infectious
agents in societies with resistant subpopulations provided
the impetus for the further study of resistance against
malaria, cholera, tuberculosis, and fungal mediated abor-
tions. It is now agreed that genetic conditions persisted to
offer resistance, which in turn enables the discovery of
potential therapeutic mechanisms. In light of this, other
genetic conditions are being explored to discover ways in
which we can combat some of the most dangerousinfectious diseases such as HIV, rabies, and Ebola, for which
there are no known cures. We have presented these re-
lationships to serve as an entry point for discussions
regarding therapy development, not only for the resistance
mechanisms discussed in this article, but also for other
discoverable mechanisms that could prove beneficial
against infectious diseases.Conflicts of interest
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